Growth factors in idiopathic pulmonary fibrosis: relative roles.
Growth factors in idiopathic pulmonary fibrosis: relative roles.
复制标题
DOI：
10.1186/rr162
复制
发表时间：
2002
影响因子：
5.8
通讯作者：
Spiteri MA
中科院分区：
文献类型：
--
作者：
Allen JT;Spiteri MA
特发性肺纤维化患者的治疗进展非常缓慢;皮质类固醇单独或与其他免疫抑制剂联合使用的基本方法对长期生存率的影响很小。由于缺乏更有效的替代品，继续使用皮质类固醇是合理的。目前的研究表明，驱动特发性肺纤维化的机制反映了肺内异常、失调的伤口愈合，涉及一系列促纤维化生长因子的活性增加和可能的过度反应。了解这些生长因子的作用，以及它们在细胞水平调节事件的方式，可能会导致更有针对性的治疗策略，提高患者的生活质量和生存率。
Treatment of idiopathic pulmonary fibrosis patients has evolved very slowly; the fundamental approach of corticosteroids alone or in combination with other immunosuppressive agents has had little impact on long-term survival. The continued use of corticosteroids is justified because of the lack of a more effective alternative. Current research indicates that the mechanisms driving idiopathic pulmonary fibrosis reflect abnormal, dysregulated wound healing within the lung, involving increased activity and possibly exaggerated responses by a spectrum of profibrogenic growth factors. An understanding of the roles of these growth factors, and the way in which they modulate events at cellular level, could lead to more targeted therapeutic strategies, improving patients' quality of life and survival.